Literature DB >> 20868567

A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behçet's disease.

Angelo Ferrante1, Francesco Ciccia, Alfonso Principato, Anna Rita Giardina, Rosalia Impastato, Sergio Peralta, Giovanni Triolo.   

Abstract

OBJECTIVES: Behçet's disease has been historically classified as a Th1 disease. The recently described IL-17/IL-23 pathway seems to play an important role in many inflammatory diseases and in the intestinal abnormalities of AS and CD. The aim of the present study was to evaluate the IL-17/IL-23 axis in parallel with Th1 and IL-27 response in the intestine of patients with BD and gastrointestinal abnormalities.
METHODS: Quantitative TaqMan reverse transcriptase-polymerase chain reaction (RT-PCR) was utilised for all determinations on ileal biopsy specimens obtained from BD, AS and CD patients. The serum levels of Th1 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay.
RESULTS: A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behçet's disease.
CONCLUSIONS: Although BD shares clinical manifestations with both CD and AS, the immunologic abnormalities seen in the intestine are quite different, indicating that other immune mechanisms should be taken into account.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868567

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

1.  Candidate Drugs Screening for Behcet's Disease Based on Bioinformatics Analysis and Mouse Experiments.

Authors:  Qinyun Xia; Chujun Lyu; Fang Li; Binbin Pang; Xiaoyu Guo; He Ren; Yiqiao Xing; Zhen Chen
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

2.  Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients.

Authors:  Cemile Sonmez; Aysegul Atak Yucel; Turan Hilmi Yesil; Hamit Kucuk; Berna Sezgin; Ridvan Mercan; Ahmet Eftal Yucel; Gulderen Yanikkaya Demirel
Journal:  Clin Rheumatol       Date:  2018-03-20       Impact factor: 2.980

3.  NOD2 is highly expressed in Behçet disease with pulmonary manifestations.

Authors:  Kamel Hamzaoui; Hanadi Abid; Anissa Berraies; Jamel Ammar; Agnès Hamzaoui
Journal:  J Inflamm (Lond)       Date:  2012-02-13       Impact factor: 4.981

4.  Serum IL-17A in Behçet's disease.

Authors:  Nazan Emiroglu; Fatma Pelin Cengiz; Gul Bahar Erdem
Journal:  Postepy Dermatol Alergol       Date:  2015-10-29       Impact factor: 1.837

Review 5.  The Role of Th17 Cells in the Pathogenesis of Behcet's Disease.

Authors:  Yuki Nanke; Toru Yago; Shigeru Kotake
Journal:  J Clin Med       Date:  2017-07-21       Impact factor: 4.241

Review 6.  Role of Subclinical Gut Inflammation in the Pathogenesis of Spondyloarthritis.

Authors:  Aroldo Rizzo; Giuliana Guggino; Angelo Ferrante; Francesco Ciccia
Journal:  Front Med (Lausanne)       Date:  2018-05-01

7.  Behҫet's Disease, and the Role of TNF-α and TNF-α Blockers.

Authors:  Tim van der Houwen; Jan van Laar
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

Review 8.  Diagnosis and management of intestinal Behçet's disease.

Authors:  Tadakazu Hisamatsu; Makoto Naganuma; Katsuyoshi Matsuoka; Takanori Kanai
Journal:  Clin J Gastroenterol       Date:  2014-04-20

9.  Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.

Authors:  Yue Li; Zelong Han; Xianfei Wang; Zhihui Mo; Wei Zhang; Aimin Li; Side Liu
Journal:  BMC Gastroenterol       Date:  2013-12-09       Impact factor: 3.067

10.  Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease.

Authors:  Giacomo Emmi; Elena Silvestri; Chiara Della Bella; Alessia Grassi; Marisa Benagiano; Fabio Cianchi; Danilo Squatrito; Luca Cantarini; Lorenzo Emmi; Carlo Selmi; Domenico Prisco; Mario Milco D'Elios
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.